Zarafonetis C J, Dabich L, DeVol E B, Rossi C, Skovronski J J
J Am Acad Dermatol. 1986 Jul;15(1):144-9. doi: 10.1016/s0190-9622(86)70150-3.
Risk of hepatotoxicity has been raised with respect to potassium para-aminobenzoate (Potaba) therapy. In this regard relevant clinical and laboratory hepatic findings in the hospital records of 390 scleroderma patients were analyzed. There were 274 patients who had received potassium para-aminobenzoate at some time and 116 who never received it. No instance was found in which potassium para-aminobenzoate was the cause of an acute hepatic hypersensitivity reaction. There were random or intercurrent abnormalities in hepatic test findings over time, but these actually occurred more often in the group of patients never treated with potassium para-aminobenzoate. Further, there was no evidence that long-term potassium para-aminobenzoate therapy is hepatotoxic. These findings suggest that acute hepatic reaction to potassium para-aminobenzoate is at least uncommon if not rare.
对氨苯甲酸酯钾（Potaba）治疗引发肝毒性的风险已受到关注。就此，分析了390例硬皮病患者医院记录中的相关临床和实验室肝脏检查结果。其中274例患者曾在某些时候接受过对氨苯甲酸酯钾治疗，116例患者从未接受过该治疗。未发现有对氨苯甲酸酯钾引发急性肝超敏反应的情况。随着时间推移，肝脏检查结果出现了随机或并发异常，但实际上这些异常在从未接受对氨苯甲酸酯钾治疗的患者组中更为常见。此外，没有证据表明长期使用对氨苯甲酸酯钾治疗具有肝毒性。这些发现表明，对氨苯甲酸酯钾引发的急性肝反应即便不罕见，至少也是不常见的。
